Sun Pharma Advanced Research Co

Sun Pharma Advanced Research Co Dividend

Dividend of Sun Pharma Advanced Research Co (SPARC.NS) as of Nov 1, 2026.

Dividend

0.00INR

Last updated:

How much dividend does Sun Pharma Advanced Research Co 2026 pay?

According to the latest status from November 2026, Sun Pharma Advanced Research Co paid a total of 0.00 INR per share in dividends within the last 12 months. With the current Sun Pharma Advanced Research Co price of 176.50 INR, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Sun Pharma Advanced Research Co Dividends

Historical Sun Pharma Advanced Research Co Dividends
PaydateDividend

The Sun Pharma Advanced Research Co Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2021
0.00 INR
Jan 1, 2022
0.00 INR
Jan 1, 2023
0.00 INR
Jan 1, 2024
0.00 INR
Jan 1, 2025
0.00 INR
Jan 1, 2026
0.00 INR
Jan 1, 2027 (e)
0.00 INR
Jan 1, 2028 (e)
0.00 INR
The Sun Pharma Advanced Research Co Dividend history
YEARDividendYoY
est0.00INR—
est0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—
0.00INR—

Is the Sun Pharma Advanced Research Co Dividend Safe?

Sun Pharma Advanced Research Co has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Sun Pharma Advanced Research Co's Dividend Distributions

Sun Pharma Advanced Research Co’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Sun Pharma Advanced Research Co's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Sun Pharma Advanced Research Co's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Sun Pharma Advanced Research Co’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Sun Pharma Advanced Research Co Stock analysis

What does Sun Pharma Advanced Research Co do? Sun Pharma Advanced Research Co Ltd develops pharmaceutical products for unmet medical needs in oncology, neurodegeneration, and immunology. The company focuses on New Chemical Entities (NCEs) such as SCC-138, SCO-088, SCO-120, and SCD-044, as well as Novel Drug Delivery Systems (NDDS) including Wrap Matrix Technology for controlled release tablets. Elepsia XR, developed using Wrap MatrixTM, is a commercialized product, while Xelpros, a BAK-free latanoprost eye drop based on Lipexelle technology, is marketed by a U.S. partner. The company also created PDP-716 eye drops for glaucoma treatment using TearAct technology. The firm generates revenue through R&D partnerships and commercialization of its drug candidates. Elepsia XR and Xelpros are sold under licensing agreements, with Xelpros marketed in the U.S. by a partner. PDP-716 is positioned for glaucoma treatment, leveraging TearAct technology. The company’s products target medical segments requiring innovative solutions, such as controlled-release formulations and eye care, with a focus on oncology, neurodegeneration, and immunology. Sun Pharma Advanced Research Co Ltd’s revenue streams include licensing agreements for its NCEs and NDDS technologies. Partners in the U.S. commercialize Xelpros, while Elepsia XR is sold directly. The company’s R&D pipeline, including SCC-138 and PDP-716, supports future revenue potential. Its focus on unmet medical needs drives partnerships with pharmaceutical firms seeking innovative drug delivery solutions. Sun Pharma Advanced Research Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sun Pharma Advanced Research Co stock

Sun Pharma Advanced Research Co paid dividends every year for the past 0 years.

Sun Pharma Advanced Research Co is assigned to the 'Health' sector.

The dividends of Sun Pharma Advanced Research Co are distributed in INR.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — Sun Pharma Advanced Research Co